CN117242349A - 用于脓毒症的早期检测的igfbp7标志物组 - Google Patents

用于脓毒症的早期检测的igfbp7标志物组 Download PDF

Info

Publication number
CN117242349A
CN117242349A CN202280031693.3A CN202280031693A CN117242349A CN 117242349 A CN117242349 A CN 117242349A CN 202280031693 A CN202280031693 A CN 202280031693A CN 117242349 A CN117242349 A CN 117242349A
Authority
CN
China
Prior art keywords
biomarker
subject
amount
assessing
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280031693.3A
Other languages
English (en)
Chinese (zh)
Inventor
F·格鲁内瓦尔德
V·J·R·杰格
M·克莱默
P·舒兹
M·冯霍尔蒂
S·韦伯
H·韦格迈尔
U-H·维恩休斯-泰伦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN117242349A publication Critical patent/CN117242349A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91188—Transferases (2.) transferring nitrogenous groups (2.6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN202280031693.3A 2021-04-30 2022-04-29 用于脓毒症的早期检测的igfbp7标志物组 Pending CN117242349A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21171492 2021-04-30
EP21171492.8 2021-04-30
PCT/EP2022/061553 WO2022229422A2 (en) 2021-04-30 2022-04-29 Igfbp7 marker panels for early detection of sepsis

Publications (1)

Publication Number Publication Date
CN117242349A true CN117242349A (zh) 2023-12-15

Family

ID=75746434

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280031693.3A Pending CN117242349A (zh) 2021-04-30 2022-04-29 用于脓毒症的早期检测的igfbp7标志物组

Country Status (5)

Country Link
US (1) US20240219404A1 (https=)
EP (1) EP4330681A2 (https=)
JP (1) JP2024516679A (https=)
CN (1) CN117242349A (https=)
WO (1) WO2022229422A2 (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2476597C (en) 2002-02-28 2011-05-17 Metanomics Gmbh & Co. Kgaa Mass spectrometry method for analysing mixtures of substances
US20090197794A1 (en) 2005-07-13 2009-08-06 Aird William C Methods of Diagnosing and Treating an Inflammatory Response
CN103123359B (zh) 2007-08-03 2015-07-29 B.R.A.H.M.S有限公司 降钙素原(pct)在患原发性非传染疾病的患者的风险分级和预后中的应用
JP5722587B2 (ja) 2009-10-13 2015-05-20 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 急性脳卒中または一過性脳虚血発作を有する患者における細菌感染の診断のためのプロカルシトニン及び抗生物質治療のガイダンス
JP5763098B2 (ja) * 2009-12-20 2015-08-12 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
JP2012159356A (ja) * 2011-01-31 2012-08-23 Mochida Pharmaceut Co Ltd 敗血症診断用組合せマーカー
RU2016112915A (ru) 2013-09-05 2017-10-09 Эф-Ай-Оу Корпорейшн Биомаркеры для раннего выявления критической или угрожающей жизни ответной реакции на заболевание и/или ответной реакции на лечение
JP6859334B2 (ja) * 2015-10-08 2021-04-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 手術前に測定した際にａｋｉのリスクを予測するためのｉｇｆｂｐ７
WO2018208684A1 (en) * 2017-05-07 2018-11-15 Astute Medical, Inc. Use of insulin-like growth factor-binding protein 7 and tissue inhibitor of metalloproteinase 2 in the management of renal replacement therapy

Also Published As

Publication number Publication date
JP2024516679A (ja) 2024-04-16
WO2022229422A3 (en) 2022-12-15
US20240219404A1 (en) 2024-07-04
WO2022229422A2 (en) 2022-11-03
EP4330681A2 (en) 2024-03-06

Similar Documents

Publication Publication Date Title
JP2026048754A (ja) 敗血症の早期検出用のｐｃｔマーカーパネル
CN117242350A (zh) 用于脓毒症的早期检测的il6标志物组
CN117280218A (zh) 用于脓毒症的早期检测的strem1标志物组
CN117295950A (zh) 用于脓毒症的早期检测的ngal标志物组
CN117242349A (zh) 用于脓毒症的早期检测的igfbp7标志物组
CN117255947A (zh) 用于脓毒症的早期检测的sFlt1标志物组
CN117203528A (zh) 用于脓毒症的早期检测的gdf15标志物组
CN117597584A (zh) 用于脓毒症的早期检测的esm1标志物组合
CN117321419A (zh) 用于脓毒症的早期检测的Presepsin标志物组
CN118043479A (zh) 用于脓毒症的早期检测的MR-proADM标志物组
CN118742814A (zh) 用于脓毒症的早期检测的dll1标志物组

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination